Surgical Science Sweden AB (publ) SUS

First North | MedTech – VR surgical training simulators
Follow Surgical Science Sweden free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Updated: 13 Nov 2026 Base analysis: 6 Apr 2026

The news check keeps the assessment current.

General analysis — not personal advice.

HOLD Clear

Wait for the Q1 report; consider a small add (up to ~10%) only after confirmed stabilization in license revenue/margins.

Strong balance sheet, higher share of license revenues and confirmed margin improvement outweigh remaining uncertainty around 2026 revenues.

Market sentiment Positive ↑
Trend: Improving

Sentiment has strengthened further after the Pareto upgrade and positive signals from Intuitive.

Risk assessment High
Dilution: Low Large net cash, no clear funding need
Jurisdiction: Low Sweden and Western markets dominate
Execution: High Must replace OEM loss and lift margins
Cash flow: 24 mo

HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.

Latest change
  • 20 Sep 2026 — The report shows higher license revenue and margin improvement after the Intuitive effect proved smaller than feared.

The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.

Show all changes (4) — follow the company free
About the company

Surgical Science Sweden AB develops VR-based simulators and software for surgical training, including robotic surgery, endoscopy and ultrasound. It sells to both education customers (hospitals/universities) and industry customers via OEM/license agreements. 2026 carries elevated uncertainty after an Intuitive-related arrangement ended, expected to reduce license revenue.

Sector: MedTech – VR surgical training simulators
Type: Other
Next report (Annual)
23 Feb 2027
Catalysts
◐
Dec 2026
Visible Intuitive effect in full-year 2026 High
Bull case

Higher share of license revenues lifts gross margin and shows the business model remains robust even amid disruptions from individual customers.

Bear case

License revenues could still decline more than expected in the second half of 2026 if the Intuitive effect materializes fully.

Why this signal

Strong balance sheet, higher share of license revenues and confirmed margin improvement outweigh remaining uncertainty around 2026 revenues.

Recent news
  • Pareto Securities raises target price to 65 SEK with reiterated buy. Intuitive Surgical reports strong Q3 growth and raises volume guidance, supporting license revenues. The stock trades around 54–55 SEK in a positive technical trend.

Key figures

Revenue
Q3 2026
SEK 260M
EBITDA
Q2 2026
SEK 54.4M
Net income
Q3 2026
SEK 34.1M
Cash
as_of
SEK 675M
Total debt
Q2 2026
SEK 0.0M
Gross margin
Q3 2026
68.0%
Exchange
First North
Sector
MedTech – VR surgical training simulators
Surgical Science Sweden AB (publ) SUS
Surgical Science Sweden — this picture changes. Follow free
Follow Surgical Science Sweden free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.